Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1977 Jun;4(3):371–372. doi: 10.1111/j.1365-2125.1977.tb00726.x

Pindolol, a beta-adrenoceptor blocking agent with a negligible first-pass effect.

J Meier, E Nüesch
PMCID: PMC1429071  PMID: 901706

Full text

PDF
371

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aellig W. H. beta-Adrenoceptor blocking activity and duration of action of pindolol and propranolol in healthy volunteers. Br J Clin Pharmacol. 1976 Apr;3(2):251–257. doi: 10.1111/j.1365-2125.1976.tb00600.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bahr C., Alván G., Lind M., Mellström B., Sjöqvist V. Proceedings: "First-pass" effect and dose dependent availability as factors contributing to interindividual differences in equilibrium concentrations of alprenolol in man. Acta Pharm Suec. 1974 Dec;11(6):649–650. [PubMed] [Google Scholar]
  3. Coltart J. Proceedings: Biological and pharmacological myocardial elimination rate of propranolol. Br Heart J. 1975 May;37(5):555–555. [PubMed] [Google Scholar]
  4. Gibaldi M., Boyes R. N., Feldman S. Influence of first-pass effect on availability of drugs on oral administration. J Pharm Sci. 1971 Sep;60(9):1338–1340. doi: 10.1002/jps.2600600909. [DOI] [PubMed] [Google Scholar]
  5. Gugler R., Herold W., Dengler H. J. Pharmacokinetics of pindolol in man. Eur J Clin Pharmacol. 1974;7(1):17–24. doi: 10.1007/BF00614385. [DOI] [PubMed] [Google Scholar]
  6. Johnsson G., Regàrdh C. G. Clinical pharmacokinetics of beta-adrenoreceptor blocking drugs. Clin Pharmacokinet. 1976;1(4):233–263. doi: 10.2165/00003088-197601040-00001. [DOI] [PubMed] [Google Scholar]
  7. Johnsson G., Regårdh C. G., Sölvell L. Combined pharmacokinetic and pharmacodynammc studies in man of the adrenergic beta1-receptor antagonist metoprolol. Acta Pharmacol Toxicol (Copenh) 1975;36(Suppl 5):31–44. doi: 10.1111/j.1600-0773.1975.tb03320.x. [DOI] [PubMed] [Google Scholar]
  8. Ohnhaus E. E., Nüesch E., Meier J., Kalberer F. Pharmacokinetics of unlabelled and 14C-labelled pindolol in uraemia. Eur J Clin Pharmacol. 1974;7(1):25–29. doi: 10.1007/BF00614386. [DOI] [PubMed] [Google Scholar]
  9. Pacha W. L. A method for the fluorimetric determination of 4-(2-hydroxy-3-isopropylaminopropoxy)-indole (LB46), a beta-blocking agent, in plasma and urine. Experientia. 1969 Aug 15;25(8):802–803. doi: 10.1007/BF01897885. [DOI] [PubMed] [Google Scholar]
  10. Regårdh C. G. Pharmacokinetics and biopharmaceutics of some adrenergic beta-receptor antagonists with special emphasis on alprenolol and metoprolol. Acta Pharmacol Toxicol (Copenh) 1975;37(1):1–39. doi: 10.1111/j.1600-0773.1975.tb03091.x. [DOI] [PubMed] [Google Scholar]
  11. Shand D. G., Rangno R. E. The disposition of propranolol. I. Elimination during oral absorption in man. Pharmacology. 1972;7(3):159–168. doi: 10.1159/000136285. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES